# C_2022262EN.01001301.xml

| 7.7.2022 | EN | Official Journal of the European Union | C 262/13 |
| --- | --- | --- | --- |

7.7.2022

EN

Official Journal of the European Union

C 262/13

---

Prior notification of a concentration

(Case M.10809 – CD&R / TPG / COVETRUS)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 262/09)

1.

This notification concerns the following undertakings:

| — | Clayton, Dubilier & Rice Fund XI, L.P. and three other limited partnerships under common control (‘CD&R’, United States), |
| --- | --- |

—

Clayton, Dubilier & Rice Fund XI, L.P. and three other limited partnerships under common control (‘CD&R’, United States),

| — | TPG Partners VIII, L.P. (‘TPG Partners VIII’), and TPG Healthcare Partners, L.P. (‘TPG Healthcare’) (‘TPG’, United States), |
| --- | --- |

—

TPG Partners VIII, L.P. (‘TPG Partners VIII’), and TPG Healthcare Partners, L.P. (‘TPG Healthcare’) (‘TPG’, United States),

| — | Covetrus, Inc. (‘Covetrus’, United States) (‘the Target’). |
| --- | --- |

—

Covetrus, Inc. (‘Covetrus’, United States) (‘the Target’).

CD&R and TPG will acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Covetrus.

The concentration is accomplished by way of purchase of shares.

2.

| — | CD&R is a private equity investment firm which has investments in various sectors of the economy, |
| --- | --- |

—

CD&R is a private equity investment firm which has investments in various sectors of the economy,

| — | TPG is a private equity fund that invests in a variety of companies through acquisitions and corporate restructuring. |
| --- | --- |

—

TPG is a private equity fund that invests in a variety of companies through acquisitions and corporate restructuring.

| — | Covetrus is a publicly listed company active globally as a provider of animal-health technology and services to companies supporting the companion, equine and large-animal veterinary markets, specifically veterinarians and animal-health practitioners. |
| --- | --- |

—

Covetrus is a publicly listed company active globally as a provider of animal-health technology and services to companies supporting the companion, equine and large-animal veterinary markets, specifically veterinarians and animal-health practitioners.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

Case M.10809 – CD&R / TPG / COVETRUS

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---